contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-and-first-control-meeting-in-asarina-pharma

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Asarina Pharma

Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the company would enter into voluntary liquidation...

<div class="mfn-preamble"><p><strong>Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the company would enter into voluntary liquidation. The general meeting adopted the following main resolutions.</strong></p></div><div class="mfn-body"><p><strong>Resolution on voluntary liquidation</strong><br>The general meeting resolved in accordance with the board of directors' proposal that the company shall enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act. The resolution on liquidation is proposed to take effect as of 1&nbsp;December 2024. The reason for this is that payments are expected to be received by the company's Danish subsidiary Asarina Pharma ApS during November. The distribution of any liquidation proceeds is expected to take place in connection with the expiry of the time for calling unknown creditors, or at the latest in connection with the presentation of the liquidator’s final report. No probate proceeds are prudently anticipated. The board of directors had not presented a proposal for a liquidator to the general meeting.</p></div><div class="mfn-footer mfn-contacts mfn-c85405f73fa6"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Paul De Potocki, Chairman of the Board of Directors<br>Phone: +46 (70) 669 9618<br>E-mail: <a rel="noopener" href="mailto:paul.depotocki@telia.com">paul.depotocki@telia.com</a></p><p>Jakob Dynnes Hansen, CFO<br>Phone: +45 5132 3698<br>E-mail: <a rel="noopener" href="mailto:jakob.dynnes@asarinapharma.com">jakob.dynnes@asarinapharma.com</a></p></div><div class="mfn-footer mfn-about mfn-6229831054f8"><p><strong class="mfn-heading-1">About Asarina Pharma</strong><br>Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments. </p><p>The Company's Certified Adviser is Carnegie Investment Bank AB (publ). E-mail: <a rel="noopener" href="mailto:certifiedadviser@carnegie.se">certifiedadviser@carnegie.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/c15781e5-99d3-4ffc-aa92-65de0fdf0d9c/bulletin-from-the-extraordinary-general-meeting-and-first-control-meeting-in-asarina-pharma.pdf" class="mfn-generated mfn-primary">Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma</a></p></div>

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Stay up to date with our newsletter